

Recurrence of hepatocellular carcinoma following liver ...

<https://pubmed.ncbi.nlm.nih.gov/32933351>

Introduction: Hepatocellular carcinoma (HCC) is an increasingly common disease with liver transplant (LT) the best long-term therapy for early stage disease. We will review the data for assessing risk and managing recurrence for patients undergoing LT for HCC. Areas covered: In this review, we will provide an overview of methods of patient risk stratification in the post-transplant period, the ...

Author: Daniel Hoffman, Neil Mehta Publish Year: 2021

Harnessing immunotherapy for liver recipients with ... 11 mins read

<https://journals.sagepub.com/doi/full/10.1177/1758835919843463>

Apr 26, 2019 · The management of hepatocellular carcinoma (HCC) recurrence after liver

Search Toc

Turn off Hover 1

Hepatobiliary cancers and immunotherapy: where are we now ...

<https://pubmed.ncbi.nlm.nih.gov/32190776>

Sep 07, 2019 · **After** CheckMate-040, nivolumab gained approval in late 2017 in the second-line setting for patients with advanced HCC and Child-Pugh A or B7 liver disease. Pembrolizumab was granted FDA approval in 2018 in the second-line setting **after** publication of KEYNOTE-224 for patients with advanced HCC and Child-Pugh A liver disease.

Cited by: 5

Author: Adam Zayac, Khaldoun Almhanna

Publish Year: 2020

Immunotherapy for advanced hepatocellular carcinoma: a ...

<https://gut.bmj.com/content/70/1/204> ▾

Jan 01, 2021 · Organ **transplantation**. **Liver transplantation** is a potential curative treatment option for patients with early-stage HCC.⁴⁰ However, around 8% to 21% of patients experience HCC recurrence, depending on tumour size and number as well as biological factors such as alpha-fetoprotein.^{41 42} Recurrent HCC **after liver transplantation** is considered a ...

Cited by: 22

Author: Matthias Pinter, Bernhard Scheiner, Markus...

Publish Year: 2021

Estimated Reading Time: 12 mins

People also ask

Which is the best treatment for advanced liver cancer? ▾

Are there any immunotherapy for advanced hepatocellular carcinoma? ▾

Name of Journal: *World Journal of Gastrointestinal Surgery*

Manuscript NO: 64238

Manuscript Type: SCIENTOMETRICS

Immunotherapy after liver transplantation: Where are we now?

Immunotherapy after liver transplantation

Abstract

BACKGROUND

There is limited evidence on safety of immunotherapy use after liver transplantation and its efficacy on treating post-liver transplant HCC recurrence.

AIM

To assess the safety of immunotherapy after liver transplant and its efficacy for treating post liver transplant HCC recurrence.

Match Overview

1	Internet 28 words crawled on 21-Jul-2020 cardiab.biomedcentral.com	1%
2	Internet 12 words crawled on 04-Nov-2020 worldjgss.wjnet.com	<1%
3	Internet 12 words crawled on 13-Jan-2019 www.usbc-hq.org	<1%
4	Internet 12 words www.ncbi.nlm.nih.gov	<1%

Recurrence of hepatocellular carcinoma following liver ...

<https://pubmed.ncbi.nlm.nih.gov/32933351>

Introduction: Hepatocellular carcinoma (HCC) is an increasingly common disease with liver transplant (LT) the best long-term therapy for early stage disease. We will review the data for assessing risk and managing recurrence for patients undergoing LT for HCC. Areas covered: In this review, we will provide an overview of methods of patient risk stratification in the post-transplant period, the ...

Author: Daniel Hoffman, Neil Mehta Publish Year: 2021

Harnessing immunotherapy for liver recipients with ... 11 mins read

<https://journals.sagepub.com/doi/full/10.1177/1758835919843463>

Apr 26, 2019 · The management of hepatocellular carcinoma (HCC) recurrence after liver

Search Toc

Turn off Hover 1